Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Manual for Picking Coastline Travel - 22025 among world's three hottest years on record, WMO says
- 3Solar storms have influenced our history – an environmental historian explains how they could also threaten our future
- 4Nigeria warns its citizens in South Africa to be cautious after march turns violent
- 5See the moon shine with Saturn in the southern sky after sunset Dec. 26
- Figuring out the Business venture Code: The Response to Building an Effective Startup
- 10 Moving Design Frill for Summer 2023
- Coffee Prices Finish Higher on Brazil Cop Concerns
- New method spots signs of Earth's primordial life in ancient rocks
- Artemis 2 astronaut Victor Glover delivers inspiring Easter message on the way to the moon (video)
- From Squid Game to Your Party! Six Entertaining Test Games That Will Have You in Join
- Mossad unveils network of Hamas terror infrastructure across Europe
- Ageless Tastefulness: An Outline of Valuable Gemstones and Adornments
- Survey: Canteen Cups With Great Warm Protection Impact
